Drug Discovery

Gilead Sciences licences portfolio of HIV antibodies from The Rockefeller University

Gilead Sciences announced that the company has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.

GHO Capital acquires CDMO Ardena

Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, together with the existing management team has acquired Ardena, a specialist contract development and manufacturing organization (CDMO) focused on early phase drug development, from Mentha Capital.

Empirico, Ionis collaborate to develop antisense oligonucleotide therapeutics

Empirico has entered into a $660m deal with Ionis Pharmaceuticals to develop novel antisense oligonucleotide therapeutics.

Schrödinger, Bayer collaborate to co-develop de novo design technology to accelerate drug discovery

Schrödinger and Bayer announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs.

Tyme, Eagle join forces to advance SM-88 in advanced cancers

Tyme Technologies and Eagle Pharmaceuticals have entered into a collaboration deal worth up to $40m restricted to the US for co-promoting the former’s lead compound SM-88 in advanced cancers.

SAB Biotherapeutics announces research collaboration with CSL Behring

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader CSL Behring.

Cancer Research UK, Bicycle Therapeutics collaborate on new immuno-oncology candidate development

Bicycle Therapeutics has joined hands with Cancer Research UK for the development of a new immune-oncology candidate.

GlycoMimetics, Apollomics announce collaboration and license agreement for GMI-1687

GlycoMimetics and Apollomics announced an exclusive collaboration and license agreement for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.

Merck enters into $2.5bn oncology deal with Taiho and Astex

Merck has joined hands with Japan’s Taiho Pharmaceutical and the UK’s Astex Pharmaceuticals in an oncology collaboration worth $2.5bn.